Tarsus Pharmaceuticals (TARS) Net Margin (2021 - 2026)

Tarsus Pharmaceuticals' Net Margin history runs 6 years deep, the most recent figure standing at 4.28% for Q1 2026.

• In Q1 2026, Net Margin rose 2769.0% year-over-year to 4.28%; the TTM figure through Mar 2026 stood at 27.84% (up 1620.0% YoY), while the FY2025 annual figure was 14.72%, up 4845.0% from the prior year.
• Net Margin for Q1 2026 stood at 4.28%, down from 3.72% in the prior quarter.
• The five-year high for Net Margin was 3.72% in Q4 2025, with the low at 3680.52% in Q1 2022.
• The 5-year median for Net Margin is 76.64% (2024), against an average of 510.13%.
• Peak annual rise in Net Margin reached 415427 bps in 2022, while the deepest fall reached 371133 bps in 2022.
• Tarsus Pharmaceuticals' Net Margin stood at 136.26% in 2022, then plunged by 138 bps to 323.63% in 2023, then surged by 89 bps to 34.76% in 2024, then jumped by 89 bps to 3.72% in 2025, then retreated by 15 bps to 4.28% in 2026.
• Business Quant data shows TARS's Net Margin at 4.28% in Q1 2026, 3.72% in Q4 2025, and 10.69% in Q3 2025.